Canadian biotech Sitka Biopharma, which is developing a new bladder cancer treatment, has named Sean Cunliffe as Chief Executive.
Sitka is a spin-off from CDRD Ventures (CVI), the commercialisation arm of the Centre for Drug Research and Development (CDRD) and the University of British Columbia (UBC).
Cunliffe has more than 30 years of pharmaceutical marketing and sales experience across a variety of therapeutic areas. Most recently, he has held senior roles at Angiotech Pharmaceutical and Neuromed Pharmaceuticals, which is now Zalicus Inc.
He has also held several leadership roles at Wyeth Pharmaceuticals, including Vice President of New Product Marketing where he co-chaired, along with Discovery, the Neuroscience and Cardiovascular leadership teams, Vice President Marketing and Global Business Manager of Neuroscience and Vice President of Cardiovascular and Gastrointestinal Marketing.
Prior to Wyeth, Cunliffe was Group Director US Marketing, Gastrointestinal and Anti-Viral Products at Glaxo Wellcome. He also held sales and marketing roles in Canada with Glaxo and Astra Pharmaceuticals before moving to the US to work in both global and US domestic commercial functions.
